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Abstract  
Low serum salivary amylase levels have been associated with a range of metabolic abnormalities, including 
obesity and insulin resistance. We recently suggested that low copy-number at the AMY1 gene, associated 
with lower enzyme levels, also increases susceptibility to obesity. To advance our understanding of the 
effect of AMY1 copy-number variation on metabolism, we compared the metabolomic signatures of high 
and low copy-number carriers. We analysed, using mass spectrometry and NMR, the sera of healthy 
normal-weight women carrying either low (LA:≤4 copies; n=50) or high (HA:≥8 copies; n=50) AMY1 
copies. Best fitting multivariate models (empirical P<1x10
-3
) of MS and NMR data were concordant in 
showing differences in lipid metabolism between the two groups. In particular, LA carriers showed lower 
levels of long- and medium-chain fatty acids, and higher levels of dicarboxylic fatty acids and 2-
hydroxybutyrate (known marker of glucose malabsorption). Taken together, these observations suggest 
increased metabolic reliance on fatty acids in LA carriers through β- and ω-oxidation and reduced cellular 
glucose uptake with consequent diversion of acetyl-CoA into ketogenesis. Our observations are in line with 
previously-reported delayed glucose uptake in LA carriers after starch consumption. Further functional 
studies are needed to extrapolate from our findings to implications for biochemical pathways. 
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Salivary α-amylase (sAA), encoded by the AMY1 gene, is produced under the control of the autonomic 
nervous system by the salivary glands. It initiates starch digestion in the mouth, yielding a mixture of 
maltose, isomaltose and glucose. Therefore, it was expected that individuals with high levels of sAA would 
show higher postprandial glycaemia, compared to low sAA counterparts. A recent study showed, 
surprisingly, the opposite effect (1). Lower serum amylase levels have been associated with susceptibility to 
metabolic abnormalities, including non-alcoholic fatty liver disease, obesity, and diabetes (2-4).  
 Salivary amylase level is strongly correlated with the copy-number (CN) at the AMY1 gene (5). 
Higher AMY1 copy-number and sAA protein levels were observed in populations traditionally consuming 
starch-rich diets compared to those consuming a low-starch diet (5). We recently confirmed AMY1 gene 
expression and protein levels in serum to be inversely correlated with obesity and suggested CN variation at 
AMY1 to be an important driver of this relationship, showing association between low amylase CN and 
increased BMI and obesity risk in both adults (6) and children (7). On the other hand, a novel study has 
suggested that CNV might not be the main factor driving the association between amylase levels and obesity 
susceptibility (8). The mechanisms by which sAA contributes to an increased risk of metabolic diseases 
remain elusive (8,9). To further investigate the role of genetic variation at the AMY1 gene on the 
metabolism, we used untargeted 
1
H-Nuclear Magnetic Resonance (NMR) and Mass Spectrometry (MS)-
based metabolomics, and compared the metabolomic profiles of a carefully selected sample of 100 healthy 
and normal-weight, age-matched women carrying either low or high AMY1 CN.  
 
 
RESEARCH DESIGN AND METHODS 
 
Study population and design. 
Only women were included to provide a more homogenous study population to maximize power, given our 
small study population. The characteristics of the women carrying high (HA;n=50) or low (LA;n=50) copies 
of the AMY1 gene are shown in Table S1. The women were selected from the prospective D.E.S.I.R. cohort 
(9) from among those for whom data on the inferred CN at the AMY1 gene were already available (6). To 
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control for the effects of potential confounders, we carefully selected two subsamples from the top and 
bottom 20% of the CN distribution (≤4; ≥8 CN). Exclusion criteria included: 1) BMI>25kg/m
2
 or 
<18.5kg/m
2
; 2) fasting glycaemia>6 mmol/l; 3) development of any metabolic disorders during 9-year 
follow-up period. Food and caloric intake were not significantly different between the HA and LA groups. 
 All participants signed a written informed consent and the study was approved by the Ethics 
Committee for the Protection of Subjects for Biomedical Research of Bicêtre Hospital (France).  
 
Serum amylase levels 
Serum pancreatic and total amylase levels were measured by enzymatic colorimetric assays with an auto-
Roche/Hitachi cobas c701 (AMY-P-20766623322 and AMYL2-03183742122, Hoffman–La Roche). The 
sAA levels were obtained by subtracting the pancreatic amylase level from the total amylase level. 
 
Mass spectrometry 
MS-based metabolomics profiling was carried out at Metabolon (Durham, NC, USA). The processing and 
analysis of samples was performed as previously described (10) (Supplementary data).  
 
1
H-Nuclear Magnetic Resonance  
Spectra of serum samples were measured at 600.13 MHz on a Bruker Avance II 600-MHz spectrometer 
(Bruker BioSpin GmbH Rheinstetten, Germany) following Beckoner et al (11). NMR spectra were phased 
and baseline corrected. Spectra were aligned using the CluPA algorithm (12) and the alanine signal used as 
reference (1.4784 ppm). Residue water signal was removed. Data were reduced to 513 bins by intelligent 
bucketing, and normalized by Total Sum Normalization. Mean centering and Pareto scaling were applied 
prior to performing the data analysis. 
 
Identification of metabolomics signatures 
We employed multivariate statistical data analyses based on projection methods. Principal Component 
Analysis (PCA) was used for the initial exploratory data analysis. Metabolomics signatures distinguishing 
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HA and LA women were identified through Projection to Latent Structures Discriminant Analysis, based on 
VIP (Variable Importance in Projection) selection (PLS-DA VIP-based) (13). Given the limited sample size, 
we used a careful and conservative approach to validate our results.  
 First, results were validated through N-fold full cross-validation, using different values of N (N=6,7,8; 
we report only results for 7-fold as Q
2
 and AUCCV - two measures to estimate the predictive ability of the 
model), as well as through 1,000 permutation testing on the HA/LA classes (13).  
 Second, to avoid overfitting we performed stability selection by Monte-Carlo subsampling: real 
differences should be present consistently, and therefore should be found even under perturbation of the data 
by subsampling (14). We generated 500 random datasets by Monte Carlo subsampling (with prior 
probability of 0.70), and then PLS-DA VIP-based was applied to each subsample, obtaining a set of 500 
discriminant models. Each model was additionally validated by N-fold full cross-validation and 1,000 
permutations of the class response. Metabolites discriminating between HA and LA were identified as those 
that were selected by >50% of all the models.  
 Both in the original and in the randomly generated datasets, the VIP threshold for the selection of 
metabolites discriminating between HA and LA classes was determined by maximising Q
2
, while the 
number of latent variables of the PLS model was calculated by maximising Q
2
 under the constraint to pass 
the permutation test. To clarify model interpretation, PLS-DA VIP-based models were post-transformed into 
the equivalent Orthogonal-PLS-DA models (OPLS-DA) where the predictive and the orthogonal part of the 
models were identified.  
 
RESULTS 
Serum amylase levels  
HA subjects showed significantly higher levels of serum sAA compared to LA counterparts (Wilcoxon 
P=6.04×10
-8
). A smaller difference was detected for the pancreatic amylase levels (Wilcoxon P=0.025), 
which is likely to be a reflection of both physiological and structural correlations between the two enzymes 
(15) (Table S1;Figure S1).  
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Model Fitting and Validation 
The analysis of the NMR and MS datasets by PCA detected the presence of 15 outliers that were excluded 
from further analysis. The major patterns within the original data were captured by a small number of 
components, three for both NMR and MS datasets. The score scatter plots in Figure 1A-1B show the 
separation of the HA and LA samples based on the PLS-DA analyses of the MS and NMR data. The 
goodness of fit and the predictive ability estimated by 7-fold cross-validation were R
2
=0.45 and 
AUCCV=0.79 for the NMR dataset and R
2
=0.71 and AUCCV=0.92 for the MS dataset. Figures 1C-1D 
compare the R
2
 and Q
2
 obtained through random permutation of the class response with what was observed 
in the original dataset (empirical P<0.001 for both R
2
 and Q
2
).  
 
Stability selection and identification of the HA/LA metabolomics signature  
All datasets generated through Monte Carlo sampling successfully passed both permutation testing and N-
fold full cross-validation, thus suggesting that model fitting in the data was not driven by a small number of 
observations. On the basis of the stability selection, we identified two signatures from MS and NMR, 
encompassing 41 metabolites and 15 signals, respectively (Tables 1-2) that provided the largest contribution 
to the discrimination of the HA and LA groups. To investigate the role of each metabolite in the 
discrimination of the two groups, we plotted the median of the VIP calculated by stability selection versus 
the correlation between the predictive latent variable of the OPLS-DA model and the measured variables. 
Since the VIP and the correlation coefficient estimate the strength and the direction of the effect 
respectively, metabolites in the right quadrant of the plot showed higher levels in the HA group, while those 
in the left quadrant higher levels in the LA group (Figures 2A-2B).  
 Metabolites from MS data were mapped into the Ingenuity Pathway Analysis Knowledge Base 
database (QIAGEN, Redwood City, CA, USA; accessed October 2015). The reference set included the 
endogenous chemicals; we chose to focus only on experimentally observed interactions with no restrictions 
on cell type or species. The top 5 most significantly enriched Molecular and Cellular Functions included 
Carbohydrate metabolism, Energy production, and Lipid metabolism (Table S2). Their most significant 
functional annotations were: Oxidation of glucose-6-phosphate (P=3.12×10
-8
), Oxidation of lipid 
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(P=1.32×10
-6
), Accumulation of acylglycerol (P=6.19×10
-8
), and triacylglycerol (P=2.85×10
-6
). Of the 41 
MS compounds, 28 (68%) were fatty acids (FAs), 17 and 11 with respectively higher and lower levels in LA 
sera, as compared to HA. Similarly, 9 of the 15 NMR signals (60%) corresponded to FAs and their levels 
were higher in LA sera.  
 Despite 
1
H-NMR experiments being highly reproducible, different lipids cannot be easily 
distinguished from each other, but are rather assigned to multiple macro-categories characterised by the 
abundance of specific aliphatic chains, and of their magnetic shielding. Therefore, since the signals of the 
lipids detected by NMR can be characterized by only the three main functional groups (CH2-CH=CH-, -
CH2-, and -CH3), we investigated their correlation with the identified MS metabolites. The strongest 
correlations (|r|>0.7) were observed between the four  dicarboxylic fatty acids (DFAs) sebacate, azelate, 
suberate, and dodecanedioate identified by MS and the -CH2- NMR bucket in the region from 1.15 and 1.19 
ppm. Interestingly the same DFAs were also strongly correlated (r>0.8) with the glucose NMR bucket at 
3.40 ppm. The BMI distribution was not different between the HA and LA groups (Wilcoxon P=0.986). 
BMI was independent of HA/LA group definition and did not have any effect on the multivariable PLS 
models (r
2
<0.01; P>0.20). We further excluded association between BMI and each single discriminant 
metabolite through linear regression considering both BMI and HA/LA level as independent variables (P for 
BMI>0.10). 
 
DISCUSSION 
In this study we aimed to explore the effect of copy-number variation at AMY1 on metabolism by comparing 
the metabolomic signature in carefully matched healthy women, carrying low or high CN at the AMY1 gene 
as reflected in a significant difference in enzyme levels between the two groups (P=6.04×10-8) (fig. S1). 
While this study design facilitates the identification of discriminant metabolites associated with AMY1 CN, 
results might be affected by spectrum bias as women were selected from the two ends of the CN 
distribution.  
 The best fitting models (empirical P<1x10
-3
) identified through multivariate analyses of the MS and 
NMR metabolomics data concordantly highlighted differences in lipid metabolism between LA and HA 
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women. Analysis of the MS discriminant metabolites using the Ingenuity Knowledge Base annotations 
confirmed the significant enrichment of functional categories for “Lipid metabolism”, “Energy production”, 
and “Carbohydrate metabolism”. In particular, the MS data showed that the levels of four DFAs, suberate, 
sebacate, azelate, and dodecanedioate, were higher in the sera from LA women compared to HA (Table 2). 
This increase in DFAs levels is suggestive of an upregulation of the ω-oxidation. In normal conditions, ω-
oxidation plays a minor role in overall FAs oxidation. However, in certain physiological states, where 
mitochondrial β-oxidation is blocked or overwhelmed, free FAs are ω-oxidized in the reticulum, by a CYP-
4A dependent pathway, to DFAs (16), which can then enter mitochondrial β-oxidation. 
 To corroborate the proposed interpretation, alongside the increase in DFAs, women with LA also 
showed lower serum concentrations of several medium and long chain fatty acids (Table 2). This reduction 
in FA levels is coherent with a more active uptake and oxidation, both via β- and ω-oxidation.   
 Interestingly, LA women also showed increased levels of 2-hydroxybutyrate, a biomarker for insulin 
resistance in humans (17) (Table 2). Taken together, these results suggest a pattern of reduced cellular 
glucose uptake, and consistent metabolic shift toward lipid exploitation, in LA women. Interestingly, NMR 
suggested a slight increase of glucose levels in LA sera.  
 In a similar line, Mandel and colleagues (18) recently published an experiment where they measured 
the dynamics of postprandial glucose and insulin following controlled starch, or glucose meals in healthy 
LA and HA carriers. While LA and HA did not show any differences after the glucose-based meal, LA 
carriers showed significantly higher glucose levels following the starch-based meal, suggesting glucose 
malabsorption after starch ingestion in people with constitutionally low salivary amylase levels. Mandel et 
al advocated that this effect might be mediated by delayed preabsorptive insulin response in the LA group 
after the starch meal.  
In summary, our results support the hypothesis that salivary α-amylase CN might play a role in glucose 
uptake, offering novel evidence to support further research on its mechanisms of action.  
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Table 1. Metabolites identified by stability selection applied to MS dataset. Upward and downward arrows in the last 
column indicate that the LA/HA ratio of the metabolite level is increased (↑) or decreased (↓) in sera from LA 
compared to HA subjects (see also Figure 2). 
 
Metabolitearial  Class  Pathway  LA/HA  
N6-acetyllysine     
   
Amino acid  
Lysine metabolism  ↑ 
Histidine  Histidine metabolism  ↓ 
2-hydroxybutyrate (AHB)  
Cysteine, methionine, SAM, taurine 
metabolism  
↑ 
Xylitol  
Carbohydrate  Nucleotide sugars, pentose metabolism  
↑ 
Ribose  ↑ 
Pyridoxate  
Cofactors and 
vitamins  
   
Pyridoxal metabolism  
  
↓ 
Succinylcarnitine  Energy  Krebs cycle  ↓ 
Sebacate (decanedioate)  
   
   
   
   
   
   
   
   
   
   
   
   
   
Lipid  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
   
   
   
   
Fatty acid, dicarboxylate  
  
  
↑ 
Azelate (nonanedioate)  ↑ 
Suberate (octanedioate)  ↑ 
Dodecanedioate  ↑ 
3-carboxy-4-methyl-5-propyl-2-
furanpropanoate (CMPF)  
↓ 
2-linoleoylglycerol (2-monolinolein)  Monoacylglycerol  ↑ 
1,2-propanediol  Ketone bodies  ↑ 
7-beta-hydroxycholesterol     
Sterol/Steroid  
  
↓ 
Campesterol  ↓ 
Cortisone  ↑ 
Taurolithocholate 3-sulfate  Bile acid metabolism  ↓ 
Oleamide  Fatty acid, amide  ↓ 
10-heptadecenoate (17:1n7)     
   
   
Long chain fatty acid  
  
↓ 
Arachidate (20:0)  ↓ 
Myristoleate (14:1n5)  ↓ 
Palmitate (16:0)  ↓ 
Myristate (14:0)  ↓ 
1-linoleoylglycerol (1-monolinolein)  Monoacylglycerol  ↑ 
2-linoleoylglycerophosphocholine     
   
Lysolipid  
↑ 
1-oleoylglycerophosphoethanolamine  ↓ 
2-oleoylglycerophosphoethanolamine  ↑ 
Pelargonate (9:0)   
Medium chain fatty acid 
 
 ↑ 
Caprate (10:0)  ↓ 
Laurate (12:0)  ↓ 
Glycerol Glycerolipid metabolism  ↓ 
Linolenate [alpha or gamma; (18:3n3 or 
6)]  
Essential fatty acid  ↓ 
Stearoyl sphingomyelin  Sphingolipid  ↓ 
13-methylmyristic acid  Fatty acid, branched  ↓ 
N-acetylcarnosine  
Peptide  
  
  
Dipeptide derivative  ↓ 
Leucylglycine Dipeptide  
 
↓ 
Leucylphenylalanine  ↓ 
Gamma-glutamylglutamate  gamma-glutamyl  ↓ 
Hwesasxx*  Polypeptide  ↑ 
Inosine  Nucleotide  Purine metabolism  ↑ 
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Table 2. Metabolites identified by stability selection applied to NMR dataset. Upward and downward arrows 
in the last column indicate that the LA/HA ratio of the metabolite level is increased (↑) or decreased (↓) in sera from 
LA compared to HA subjects (see also Figure 2). The signal of metabolites was defined with reference to 
alanine (1.4784 ppm).  
Metabolite  Class  Pathway  LA/HA  From ppm  To ppm  
Urea    Urea cycle  ↑ 5.25 5.29 
D-glucose  
Carbohydrate Glycolysis  
↑ 3.39 3.39 
Lactic acid  ↓ 1.33 1.34 
Lactic acid  ↓ 1.32 1.33 
Glutamate    
Glutamate/glutamine 
metabolism  
↓ 2.03 2.07 
Fatty acids CH2-
CH=CH-  
Lipid  Lipid metabolism  
↑ 1.97 2.01 
Fatty acids -CH2- ↑ 1.28 1.32 
Fatty acids -CH2- ↑ 1.23 1.27 
Fatty acids -CH2- ↑ 1.19 1.23 
Fatty acids -CH2- ↑ 1.15 1.19 
Linoleic chain  ↑ 0.88 0.92 
Fatty acids -CH3  ↑ 0.83 0.88 
Fatty acids -CH3  ↑ 0.75 0.79 
Fatty acids -CH3  ↑ 0.71 0.75 
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FIGURE LEGENDS 
 
Figure 1. PLS-DA VIP-based models for MS and NMR datasets. The goodness of fit and predictive ability 
estimated by 7-fold full cross-validation were R2=0.45, Q2=0.25 (AUCCV=0.79) for MS dataset and R
2=0.71, 
Q2=0.40 (AUCCV=0.92) for NMR dataset. A and B: score scatter plots obtained after the transformation of 
the PLS-DA VIP-based models into OPLS-DA models for the MS (A) and NMR (B) datasets. The samples 
are coloured according to the class: HA (grey dots) and LA (black dots). The x-axis represents the 
predictive latent variable tp providing a clear class separation of LA against HA while the y-axis is the first 
orthogonal latent variable to1 that is not related to the class samples. C and D: plot for the response 
permutation test (1,000 random permutations) of the models built for MS (C) and NMR (D). The x-axis 
represents the correlation between the class response Y and the random permutated class response Yp 
while the y-axis reports the values of R2 and Q2 for the calculated PLS-DA VIP-based models. Most of the 
models having low correlation between permutated response and the class response shows negative Q2 
and the related R2 is always lower than that calculated for the reference model (i.e. the model 
corresponding to cor(Yp,Y)=1). This behaviour proves the absence of overfitting in the reported models. 
 
Figure 2.  VIP versus cor(tp,x) plot for the OPLS-DA models of the MS (A) and NMR (B) datasets reporting 
the metabolites  identified by stability selection. The x-axis shows the direction of the effects of the 
metabolites on the model expressed as cor(tp,x) while the y-axis reports the strength of their contribution to 
the model (VIP): metabolites on the left of the origin are overrepresented in LA (negative values for 
cor(tp,x)) while metabolites on the right of the origin are overrepresented in HA (positive values for 
cor(tp,x)); the strength of the metabolite in the separation between LA and HA increases according to the 
VIP value. 
 
 
Page 15 of 22 Diabetes
Figure 1
cor(yp,y) 
-0.3 
-0.15 
0 
0.2 
0.4 
0 0.4 0.8 
R2 
Q2 
C 
cor(yp,y) 
-0.4 
0 
0.4 
0.8 
0 0.4 0.8 
R2 
Q2 
D 
B 
tp[1] 
-8 
-4 
0 
4 
8 
-4 -3 -2 -1 0 1 2 3 
to
[1
] 
HA 
LA 
A 
tp[1] 
-0.6 
-0.4 
-0.2 
0 
0.2 
0.4 
-0.2 -0.1 0 0.1 0.2 
to
[1
] 
HA 
LA 
Page 16 of 22Diabetes
Figure 2
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SUPPORTING MATERIAL 
MATERIALS 
SAMPLE SELECTION. 
Inferred AMY1 copy numbers were already available in a sample of 2,137 participants from the D.E.S.I.R. 
cohort, selected for not showing any evidence of incident diabetes, glucose intolerance, or dyslipidemia 
over the course of a nine year follow-up (Falchi et al 2014). Serum amylase data (total, pancreatic, and 
salivary) were measured in these subjects. 
For this metabolomics analysis, we aimed to select, among those with available AMY1 CNV data, two 
homogenous groups who differed only in the number of copies of the salivary amylase gene.  
We reasoned that many factors including age, sex, and metabolic disease, may alter metabolite levels as 
identified through mass spectrophotometry and NMR,, that could therefore act as potential confounders 
in our study. 
Starting with 2,137 people, we first selected those of normal weight (18.5 < BMI < 25 kg/m²; N=1,259), 
of whom 800 were women, with ages ranging from 30 to 65 years. We selected a younger subset of 280 
women aged between 30 and 40 years. Of these, 60 had predicted AMY1 CN <=4 (LA) and 86 CN>=8 
(HA) – which represent, respectively, the first and third quartile of the copy number distribution observed 
in this population. Availability of nine years of follow-up data in the D.E.S.I.R. cohort reduces the 
possibility that underlying (and undetected) predisposition to metabolic disorders was present in women 
belonging to the two selected groups, thus reducing potential confounding from factors that could have 
been disproportionately prevalent in one of the two genotype groups. 
Fifty age-matched women were selected from each of the two LA/HA groups. No significant differences 
in self-reported food preference and intake nor sporting activity were detected between the two groups. 
Finally, serum salivary amylase levels were used to validate the genetic data and verify whether low and 
high copy number at AMY1 was also reflected in high and low serum amylase levels. 
 
MASS SPECTROMETRY 
The metabolon analytical platform consisted of two separate ultra-high performance liquid 
chromatography/tandem mass spectrometry devices (UHPLC/MS/MS2), optimized one for basic and 
acidic species, and one for GC/MS. Each sample was run simultaneously on the 3 analytic machines. 
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Metabolites were identified by automated comparison of the ion features in the experimental samples to a 
reference library of chemical standard entries that included retention time, molecular weight (m/z), 
preferred adducts, and in-source fragments as well as their associated MS/MS2 spectra. This integrated 
platform enables the high-throughput collection and relative quantitative analysis of analytical data and 
identifies a large number and broad spectrum of molecules with a high degree of confidence.  Analytical 
repeatability was assessed by calculating the median relative standard deviation (RSD) for the internal 
standards that were added to each sample prior to injection into the mass spectrometers. Values for 
instrument and process variability were below significance threshold (<5%). 
Prior to statistical analysis, we applied a conservative missing value cut off of 20% to the raw area count 
values, which led to the exclusion of 40 metabolites.  407 biochemicals thus remained for further analysis. 
Missing values for the remaining metabolites were inputted using the observed minimum detection value. 
Normalization was performed by Median Fold Change Normalization and autoscaling applied prior to 
performing the data analysis. 
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TABLES 
Table S1. Comparison of age, metabolic parameters, and serum amylase levels (total, pancreatic, salivary) 
between women included in the HA and LA groups. Values are reported as mean (SD). Potential 
differences in quantitative variables between groups were tested by non-parametric Wilcoxon tests. No 
significant difference in the variance of these variables (Levene test P value > 0.05) was observed between 
the HA and LA groups. The BMI distribution does not differ between the two groups (Wilcoxon rank sum 
test P value = 0.986), and adjusting the variables compared in table S1 for BMI had a negligible effect on 
the test results. 
 High AMY1 CN High AMY1 CN P value 
Age in years ± SD 36 ± 3.3 35 ± 3.2 ns 
Average BMI (kg/m
2
) ± SD 22 ± 2.0  21.5 ± 1.8 ns 
Average HbA1c (%; mmol/mol) ± SD 5.00 ± 0.24 
(31.26  ±  2.66) 
4.93 ± 0.35 
(31.22  ±  3.88) 
ns 
Fasting glucose (mg/dl) 4.89 ± 0.38 4.89 ± 0.37 ns 
Serum total amylase (U/L) ± SD 77.22 ± 36.34 50.82 ± 17.7 6.40×10
-6
 
Serum pancreatic amylase (U/L) ± SD 32.8 ± 23.48 26.58 ± 10.56 0.025 
Serum salivary amylase (U/L) ± SD 44.39 ±19.58 24.24 ± 15.04 6.04×10
-8
 
 
 
Page 20 of 22Diabetes
Table S2. Top 5 Molecular and cellular Functions categories identified by IPA knowledgebase analysis 
using the discriminant metabolites identified in this study. 32 out of 41 molecules were mapped into the 
IPA knowledgebase analysis. The top 5 Molecular and cellular Functions included (with P<0.05) Cell 
Death and survival, Carbohydrate metabolism, Energy production, Lipid metabolism, Small molecule 
Biochemistry. The top functional annotations shared by the latest 4 categories where the Oxidation of 
glucose-6-phosphate (P=3.12×10-8), Oxidation of lipid (P=1.32×10-6) and Accumulation of 
acylglycerol (P=6.19×10-8) and triacylglycerol (P=2.85×10-6). 
Name P value range # Molecules 
Cell Death and survival 4.48×10-2 - 2.23×10-9 10 
Carbohydrate metabolism 3.76×10-2 - 3.12×10-8 7 
Energy production 3.76×10-2 - 3.12×10-8 3 
Small molecule biochemistry 4.10×10-2 - 3.12×10-8 12 
Lipid metabolism 4.10×10-2 - 6.19×10-8 9 
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FIGURES 
Figure S1.  Whisker diagram of salivary (A) and pancreatic (B) amylase levels measured in serum 
samples obtained from individuals displaying low (LA; n=50) or High (HA; n=50) copies of the AMY1 
gene. The concentration of salivary amylase was obtained by subtracting the pancreatic amylase level 
from the total amylase level. 
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